Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HER2 + Breast Cancer: early-phase trial registry
6 of 9 indexed HER2 + Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count
HER2 + Breast Cancer: 9 US clinical trials tracked, 6 recruiting.
HER2 + Breast Cancer is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Nagoya City University, running 1 of these trials.
Enrollment posture brief
Registry condition her2-breast-cancer
OPEN 6 | RECR 67% | LATE 0 | EARLY 6 | RANK #1916 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
HER2 + Breast Cancer lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HER2 + Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HER2 + Breast Cancer is recruiting above its size-band peers.
6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of HER2 + Breast Cancer trials is spread across many organizations.
Nagoya City University accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical HER2 + Breast Cancer enrolment sits around 50 participants.
Median target enrolment is 50 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.
-
HER2 + Breast Cancer splits between interventional and observational designs.
6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
HER2-positive Breast Cancer Registry
Priyanka Sharma
NCT06603597
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Tempus AI
NCT07211178
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT07222215
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics
NCT06253871
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05534438
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Calibr, a division of Scripps Research
NCT06878248
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)
Nagoya City University
NCT06663787
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
Herbert Lyerly
NCT03632941
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Washington University School of Medicine
NCT06844669
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on HER2 + Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HER2 + Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HER2 + Breast Cancer page
9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 HER2 + Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nagoya City University sponsors the most HER2 + Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Nagoya City University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2 + Breast Cancer condition card totals 9 registered trials; most-linked intervention VRP-HER2; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.